AKRO

Akero Therapeutics
AKRO

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$4.43B
EV
$3.34B
Shares Outstanding
83.86M
Beta
-0.16

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$76.30
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Akero Therapeutics, Inc.

gainify
AKRO

Akero Therapeutics, Inc.

AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that pro...

Sector

Healthcare

Industry

Biotechnology

CEO

Cheng, Andrew

Employees

69

IPO Date

2019-06-20

Headquarters

601 Gateway Boulevard, Suite 350, South San Francisco, California, 94080, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.